We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
Summit Therapeutics Plc | LSE:SUMM | London | Ordinary Share | GB00BN40HZ01 | ORD 1P |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.00 | 0.00% | 20.50 | 18.00 | 23.00 | 0.00 | 01:00:00 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
0 | 0 | N/A | 0 |
TIDMSUMM Summit Therapeutics plc ('Summit' or the 'Company') Exercise of Restricted Stock Units Oxford, UK, and Cambridge, MA, US, 24 December 2019 -- Summit Therapeutics plc (NASDAQ: SMMT, AIM: SUMM) announces the exercise by Leopoldo Zambeletti, a Non-Executive Director of Summit, of restricted stock units ('RSUs') that entitled the holder to subscribe for an ordinary share of one penny nominal value at a subscription price of one penny per ordinary share. The RSUs were granted under the Company's 2017 Remuneration Policy and were eligible for exercise for a limited time after completion of a vesting period of one year. Details of the exercise of the RSUs, all of which took place on 23 December 2019, and which have been duly notified to the Company, are summarised below. % of Issued RSU's Shareholding Share Director Position Exercised (ordinary shares) Capital ------------- -------------- ------------- ------------------ ------------ Leopoldo Non-Executive Zambeletti Director 17,073 33,052 0.02% ------------- -------------- ------------- ------------------ ------------ Application has been made to the London Stock Exchange for the admission of 17,073 ordinary shares to trading on AIM and it is expected that admission will become effective and that dealings will commence at 8.00 a.m. on or around 31 December 2019. About Summit Therapeutics Summit Therapeutics is a leader in antibiotic innovation. Our new mechanism antibiotics are designed to become the new standards of care for the benefit of patients and create value for payors and healthcare providers. We are currently developing new mechanism antibiotics for infections caused by C. difficile, N. gonorrhoeae and ESKAPE pathogens and are using our proprietary Discuva Platform to expand our pipeline. For more information, visit www.summitplc.com and follow us on Twitter @summitplc. Contacts Summit Richard Pye (UK office) Tel: +44 (0)1235 443 951 Michelle Avery (US office) +1 617 225 4455 Cairn Financial Advisers LLP (Nominated Adviser) Tel: +44 (0)20 7213 0880 Liam Murray / Tony Rawlinson Notification of Transactions pursuant to Article 19(1) of Regulation (EU) No. 596/2014 1 Details of the persons discharging managerial responsibilities/person closely associated -------------------------------------------------------------------------------------- a) Name (i) Leopoldo Zambeletti ------------------------ ------------------------------------------------------------ 2 Reason for the notification -------------------------------------------------------------------------------------- a) Position / status (i) Non-Executive Director ------------------------ ------------------------------------------------------------ b) Initial notification / Initial notification Amendment ------------------------ ------------------------------------------------------------ 3 Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor -------------------------------------------------------------------------------------- a) Name Summit Therapeutics plc ------------------------ ------------------------------------------------------------ b) LEI 213800NRW8AOMYMTBD89 ------------------------ ------------------------------------------------------------ 4 Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted -------------------------------------------------------------------------------------- a) Description of the Ordinary shares of 1 penny each financial instrument, type of instrument Identification code GB00BN40HZ01 ------------------------ ------------------------------------------------------------ b) Nature of the Exercise of restricted stock units (RSUs) to subscribe transactions for ordinary shares of one penny nominal value ------------------------ ------------------------------------------------------------ c) Price(s) and volume(s) Price(s) Volume(s) ------------------------ ----------------------------- ------------------------- (i) 1p (exercise price) (i) 17,073 ------------------------ ----------------------------- ------------------------- d) Aggregated information - Aggregated volume 17,073 ordinary shares - Price 1 penny (exercise price) ------------------------ ------------------------------------------------------------ e) Date of the transactions 23 December 2019 ------------------------ ------------------------------------------------------------ f) Place of the Outside a trading venue transactions ------------------------ ------------------------------------------------------------ -END-
(END) Dow Jones Newswires
December 24, 2019 02:00 ET (07:00 GMT)
Copyright (c) 2019 Dow Jones & Company, Inc.
1 Year Summit Therapeutics Chart |
1 Month Summit Therapeutics Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions